- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Turning Point Therapeutics is a biotechnology business based in the US. Turning Point Therapeutics shares (TPTX) are listed on the NASDAQ and all prices are listed in US Dollars. Turning Point Therapeutics employs 267 staff and has a trailing 12-month revenue of around $1 million.
Our top picks for where to buy Turning Point Therapeutics stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Turning Point Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – TPTX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Turning Point Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Turning Point Therapeutics stock price (NASDAQ: TPTX)
Use our graph to track the performance of TPTX stocks over time.Turning Point Therapeutics shares at a glance
Information last updated 2024-06-30.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $75.36 |
| 200-day moving average | $48.05 |
| Wall St. target price | $71.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-5.57 |
Is it a good time to buy Turning Point Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Turning Point Therapeutics financials
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $30.8 million |
| Return on assets TTM | -22.13% |
| Return on equity TTM | -36.8% |
| Profit margin | 0% |
| Book value | $15.90 |
| Market Capitalization | $3.8 billion |
TTM: trailing 12 months
Turning Point Therapeutics share dividends
We're not expecting Turning Point Therapeutics to pay a dividend over the next 12 months.
Turning Point Therapeutics share price volatility
Over the last 12 months, Turning Point Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Turning Point Therapeutics's is -0.1941. This would suggest that Turning Point Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Turning Point Therapeutics has bucked the trend.
Turning Point Therapeutics overview
Turning Point Therapeutics, Inc. , a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.
Frequently asked questions
What percentage of Turning Point Therapeutics is owned by insiders or institutions?Currently 0.701% of Turning Point Therapeutics shares are held by insiders and 92.519% by institutions. How many people work for Turning Point Therapeutics?
Latest data suggests 267 work at Turning Point Therapeutics. When does the fiscal year end for Turning Point Therapeutics?
Turning Point Therapeutics's fiscal year ends in December. Where is Turning Point Therapeutics based?
Turning Point Therapeutics's address is: 10628 Science Center Drive, San Diego, CA, United States, 92121 What is Turning Point Therapeutics's ISIN number?
Turning Point Therapeutics's international securities identification number is: US90041T1088 What is Turning Point Therapeutics's CUSIP number?
Turning Point Therapeutics's Committee on Uniform Securities Identification Procedures number is: 90041T108
More resources on Finder
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question